Home » Newsletters » BioWorld Science

BioWorld Science

June 22, 2021

View Archived Issues

Enrollment opens in phase I study of DCC-3116 in advanced solid tumors with RAS or RAF mutations

First-in-human study of ChAdOx1 RVF vaccine candidate begins at University of Oxford

Origo Biopharma patents TGFBR1 inhibitors

BioNTech initiates first-in-human study of BNT-152 and BNT-153 in solid tumors

Medshine Discovery discloses Chk1 inhibitors for pancreatic cancer

New GTPase KRAS mutant inhibitors presented by Taiho Pharmaceutical

Lunan Pharmaceutical Group describes oleanane cinnamamide derivatives

European researchers identify CaSR-targeting antibodies

City of Hope National Medical Center presents FIH data on COH04S1 vaccine

Promising data reported from CYAD-211 IMMUNICY-1 trial

Initial phase I data on Betalutin in relapsed/refractory DLBCL

Phase II trial of Auxora in patients with acute pancreatitis and accompanying SIRS and hypoxemia

Stimulation of optic nerve activity increases optic glioma growth in mice with Nf1 mutations

Results from first-in-human study of AO-176 in advanced solid tumors

STING inhibitors target inflammatory diseases

Anti-COX-2 Ab is a novel highly specific diagnostic marker in immune aplastic anemia

Sanofi Pasteur and Translate Bio begin phase I trial of mRNA seasonal influenza vaccine

Dicerna begins phase II study of belcesiran for AAT deficiency-associated liver disease

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists
BioWorld Science
Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the...